Insulin biosimilar - Wockhardt

Drug Profile

Insulin biosimilar - Wockhardt

Alternative Names: Recombinant (r-DNA) regular short acting human insulin - Wockhardt; Wosulin-R

Latest Information Update: 14 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wockhardt
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 1 diabetes mellitus

Most Recent Events

  • 29 Aug 2016 Wockhardt plans a phase I trial for Type-1 diabetes mellitus (In volunteers) in India (CTRI2016-02-006645)
  • 29 Aug 2016 Wockhardt terminates phase I bioequivalence trial in Type-1 diabetes mellitus in India (CTRI2015-05-005801) before August 2016
  • 25 Jul 2016 Wockhardt initiates enrolment in a phase I trial for Type-1 diabetes mellitus in India (CTRI2016-07-007117)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top